November 18, 2020

Clinical Performances of Three Fully Automated Anti-SARS-CoV-2 Immunoassays Targeting the Nucleocapsid or Spike Proteins

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): testing

Both commercial spike and nucleocapsid serologic tests have approximately equivalent sensitivity for clinical diagnosis after PCR-confirmed SARS-CoV-2 infection. A study of 137 samples from 96 patients evaluating three commercial anti‐SARS‐CoV‐2 antibody assays for the detection of COVID-19 reactive antibodies reported equivalent sensitivities (range 70.4%-85.2%) within 14 days from symptom onset to PCR-confirmed diagnosis. At 28 days following symptom onset, the sensitivity increased in all assays (range 97.5-100%). The three assays were EUROIMMUN anti‐SARS‐CoV‐2 nucleocapsid (IgG) ELISA, Elecsys anti‐SARS‐CoV‐2 nucleocapsid (total antibodies) assay, and LIAISON anti‐SARS‐CoV‐2 spike proteins S1 and S2 (IgG) assay.

Favresse et al. (Nov 17, 2020). Clinical Performances of Three Fully Automated Anti-SARS-CoV-2 Immunoassays Targeting the Nucleocapsid or Spike Proteins. Journal of Medical Virology. https://doi.org/10.1002/jmv.26669